10266
|
ETCTN
|
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10268
|
ETCTN
|
Randomized Phase II Trial of Topotecan plus M6620 (VX-970) vs. Topotecan alone in Patients with Relapsed Small-Cell Lung Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10272
|
NCORP-National Institutes of Health
|
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
10273
|
ETCTN
|
A Phase 1 Study of M3814 in combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10276
|
ETCTN
|
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10285
|
ETCTN
|
Phase 1/2 Study of an EZH2 inhibitor (tazemetostat) in combination with dual BRAF/MEK inhibition in patients with BRAF-mutated metastatic melanoma who progressed on prior BRAF/MEK inhibitor therapy
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10287
|
ETCTN
|
A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone receptor positive, HER2 negative metastatic breast cancer (FAC vs FA)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10291
|
ETCTN
|
A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10292
|
ETCTN
|
DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10296
|
ETCTN
|
Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive (HER2+) metastatic breast cancer (MBC) with PIK3CA mutation or PTEN mutation
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|